Introduction
============

African hedgehogs (*Atelerix albiventris*) are increasingly becoming popular domestic pets in western countries. Neoplasia has been progressively reported in this species, with cancer being diagnosed in up to 50.00% of older hedgehogs.^[@B1],[@B2]^ Most of these neoplasms are malignant and are associated with a poor prognosis.^[@B1]^ The skin and adnexa are the most commonly affected locations; however, tumors have been reported in different body locations.^[@B1],[@B3]^ From the histogenetic perspective, the large majority of cancers observed in African hedgehogs are of epithelial origin, with documented cases of differently localized carcinomas of skin and adnexa, as well as epithelial tumors of the digestive, endocrine, respiratory and reproductive systems.^[@B1]-[@B4]^ Oral squamous cell carcinoma (SCC) is a common form of malignancy in hedgehogs and usually presents as a locally invasive tumor with a low tendency to metastasize. ^[@B1],[@B4],[@B5]^

Electrochemotherapy (ECT) is a loco-regional therapy that combines the administration of chemotherapy drugs with electric pulses displaying high voltage and square or biphasic shape.^[@B6]^ Electric pulses permeabilize the tumor cell membrane and this, in turn, enhances the delivery of lipophobic drugs such as bleomycin and cisplatin. The consequences are augmented local efficacy of the drugs with the possibility to use decreased doses of chemo-therapy agents, thus limiting morbidities while preserving effectiveness.^7^The ECT is actually considered among the different accepted therapeutic strategies that are used to treat tumors in pets. In this article, we present the first case of cancer in an African hedgehog treated with ECT.

Case Description
================

A five-year-old female spayed hedgehog was referred for an oral mass rapidly growing over one-month period. The animal was quiet, alert and responsive and a 1.00 × 1.50 cm ulcerated mass was protruded on rostral mandible ([Fig. 1A](#F1){ref-type="fig"}). The patient was anesthetized using intramuscular 0.10 mg kg^-1^ butorphanol tartrate (Dechra, Turin, Italy) combined with 0.10 mg kg^-1^medetomidine (Dechra) followed by 3.00% isoflurane (Baxter, Deerfield, USA) on oxygen administered using a small induction chamber and the lesion was biopsied. The animal was discharged on oral meloxicam (0.10 mg kg^-1^, q24hr; Boehringer Ingelheim, Milan, Italy), enrofloxacin (7.50 mg kg^-1^, q24hr; Bayer, Milan, Italy) and ranitidine (0.10 mg kg^-1^; q12hr, Ceva, Agrate Brianza, Italy), all for seven days. The tissue was fixed in 10% buffered formalin and embedded in paraffin. Four µm thick sections were stained with hematoxylin and eosin.

![**A)** The five-year-old female spayed hedgehog at presentation; **B)** The histopathological appearance of the lesion: The tumor tissue is composed of trabeculae and cords of neoplastic cells with invasive growth, disruption of the basement membrane and extension into the underlying tissue (Hematoxylin and Eosin, original magnification 10×); **C)**The tumor mass is being injected with bleomycin; **D)** Permeabilizing electric pulses are delivered to the patient through caliper electrodes connected to Onkodisruptor^®^ electroporator; **D, inset)** An approximate 25.00% tumor reduction is visible after ECT treatment](vrf-9-379-g001){#F1}

Results
=======

The histopathology report came back with a diagnosis of incompletely excised moderately differentiated SCC characterized by squamous differentiation and invasive growth with basement membrane disruption ([Fig. 1B](#F1){ref-type="fig"}). Due to the advanced stage of the neoplasm and the fact that these pets cannot correctly feed themselves in case of mandibulectomy, surgery was not a therapeutic option. At this point, the options to increase the chances of local control were included radiation therapy (modifying protocols already in use for ferrets) or electrochemo-therapy.^[@B7],[@B8]^ The owner elected the patient to be treated with ECT. After providing total body radiographs to rule out metastatic spread, the tumor mass was injected with bleomycin (Bleomicina Solfato; Sanofi Aventis, Milan, Italy) at the concentration of 1.50 mg mL^-1^ (total volume of 1 mL), ([Fig. 1C](#F1){ref-type="fig"}). Five min after the injection, trains of 8 biphasic pulses at the voltage of 1200 V cm^-1^, 1 Hz frequency, lasting 50 + 50 µsec with 300 µsec interpulse (total treatment time per cm of 3.20 msec) were administered using a clinical electroporator (Onkodisruptor^®^, Biopulse Ltd., Naples, Italy) certified for veterinary use ([Fig. 1D](#F1){ref-type="fig"}). The procedure was performed with the patient under anesthesia as described above. The patient did not show any side effects due to the therapy and was discharged. The patient experienced a 25.00% tumor reduction ([Fig. 1D](#F1){ref-type="fig"}, inset) and monthly ECT was performed thereafter combined with total body radiographs.

The patient's disease remained stable for a total of five months, then progressed and, at that time, the owner elected euthanasia.

Discussion
==========

The SCCs of the oral cavity of African pygmy hedgehogs have been well-documented.^[@B1]^ Oral SCC is the most frequently diagnosed neoplasia of the digestive tract in this species and the third most frequent cancer, after mammary gland adenocarcinoma and lymphoma.^[@B3]^ Oral SCC is usually described as a locally invasive tumor, although one review has mentioned a case associated with metastasis to lymph node and lungs.^[@B2]^ The other reported location of SCC in hedgehogs is the skin.^[@B3]^

The ECT successfully combines the administration of lipophobic antitumor agents such as bleomycin with permeabilizing high voltage electric pulses to treat several tumor histotypes in different body locations.^[@B7]^ Exclusive features of ECT such as high selectivity and efficacy for hitting neoplastic targets while at the same time sparing the local immune response and the connective organ scaffold are making this technique a valuable clinical asset.^[@B8]^ Bleomycin was chosen since it is the drug of election for ECT that greatly increases its uptake, the dose was calculated following the literature guidelines.^[@B9]^

Oral SCC has been described in hedgehogs, but the advanced stage of disease and its rapid progression prevented therapeutic approaches resulting in death of the pets.^3^ These data are consistent with our case that developed a single non-healing ulcerated lesion that remained localized in mandible without systemic spread.

The histopathology report described a moderately differentiated SCC as per current literature. The location of the lesion prevented surgical excision, orienting us towards palliative approaches. Due to the absence of reports on systemic chemotherapy in Erinaceidae, the authors elected to treat the hedgehog with locally injected bleomycin. To maximize its efficacy, trains of permeabilizing electric pulses were administered as described.^[@B10]^ The ECT allowed for extended tumor control without side effects and with a preservation of stomatognathic function. The ECT has been proved to be an effective therapeutic strategy in veterinary oncology on different tumor histotypes and animal species.^[@B11]^ In our patient, we had an enhanced efficacy and lack of chemotherapy toxicity. The shorter duration of the train of pulses also accounted for the limited morbidity observed in our patient. In conclusion, ECT is a reliable strategy that could be considered among the oncological therapies in exotic pets as an adjunct post-surgical treatment or for palliative purposes. To the best of our knowledge, this is the first reported case of ECT not only in African hedgehogs but also in exotic mammals. Further investigations are warranted to validate these preliminary observations in exotic pets to consolidate the use of this alternative therapy in such species. It is well known that the chemotherapy protocols in exotic pets (including also birds and reptiles) are still in a very early stage of development and ECT, due to its local applications is becoming an appealing and recognized therapeutic alternative, as evidenced by recent publications.^[@B12]^
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